Mitochondrial dysfunction in liver failure requiring transplantation. by Lane, Maria et al.
ORIGINAL ARTICLE
Mitochondrial dysfunction in liver failure
requiring transplantation
Maria Lane1 & Veronika Boczonadi1 & Sahar Bachtari2 & Aurora Gomez-Duran1 &
Thorsten Langer3 & Alexandra Griffiths1 & Stephanie Kleinle4 & Christine Dineiger4 &
Angela Abicht4 & Elke Holinski-Feder4 & Ulrike Schara5 & Patrick Gerner2,6 &
Rita Horvath1
Received: 6 October 2015 /Revised: 10 January 2016 /Accepted: 10 March 2016 /Published online: 6 April 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Liver failure is a heterogeneous condition which
may be fatal and the primary cause is frequently unknown.
We investigated mitochondrial oxidative phosphorylation in
patients undergoing liver transplantation. We studied 45 pa-
tients who had liver transplantation due to a variety of clin-
ical presentations. Blue native polyacrylamide gel electro-
phoresis with immunodetection of respiratory chain com-
plexes I-V, biochemical activity of respiratory chain com-
plexes II and IV and quantification of mitochondrial DNA
(mtDNA) copy number were investigated in liver tissue col-
lected from the explanted liver during transplantation.
Abnormalmitochondrial function was frequently present in this
cohort: ten of 40 patients (25 %) had a defect of one or more
respiratory chain enzyme complexes on blue native gels, 20
patients (44 %) had low activity of complex II and/or IV and
ten (22 %) had a reduced mtDNA copy number. Combined
respiratory chain deficiency and reduced numbers of mitochon-
dria were detected in all three patients with acute liver failure.
Low complex IV activity in biliary atresia and complex II de-
fects in cirrhosis were common findings. All six patients diag-
nosed with liver tumours showed variable alterations in mito-
chondrial function, probably due to the heterogeneity of the
presenting tumour. In conclusion, mitochondrial dysfunction
is common in severe liver failure in non-mitochondrial condi-
tions. Therefore, in contrast to the common practice detection
of respiratory chain abnormalities in liver should not restrict the
inclusion of patients for liver transplantation. Furthermore, im-
proving mitochondrial function may be targeted as part of a
complex therapy approach in different forms of liver diseases.
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Introduction
Liver failure is a rare but life-threatening critical illness requir-
ing intensive care that occurs when large parts of the liver
become severely damaged resulting in severe liver dysfunc-
tion. Symptoms include jaundice, encephalopathy, bleeding
problems, fatigue and lactic acidosis. Treatment of liver failure
is symptomatic, however, transplantation can be lifesaving in
severe cases (Chinnery and DiMauro 2005; Fellman and
Kotarsky 2011).
Although the cause of liver failure is often unknown,
inherited disorders of mitochondrial oxidative phosphoryla-
tion, fatty acid oxidation, the urea cycle or glycogen storage
may be responsible, especially in childhood (Casey et al 2012).
Other causes of liver failure include biliary atresia, cirrhosis,
tumours, intoxications and infections such as cytomegalovirus,
adenovirus and hepatitis A, B and C (Iwama et al 2011).
As the liver is a vital organ with a wide range of functions it
is highly dependent on ATP and a functioning oxidative phos-
phorylation system (Chinnery and DiMauro 2005). In general,
when liver disease occurs with extra-hepatic involvement
there is more reason to suspect a mitochondrial condition
(Rahman 2013), however, isolated hepatic failure may also
be related to mitochondrial dysfunction (Tables 1 and 2).
Mitochondrial hepatopathies are most frequently caused by
defects of mitochondrial DNA (mtDNA) maintenance such
as mtDNA deletion (Pearson syndrome) and depletion
(Rahman 2013). Genetic forms of mtDNA depletion are asso-
ciated with a predominant hepatopathy, however, other organs
(including muscle and brain) may also be involved (Fellman
and Kotarsky 2011), such as in epileptic encephalopathy, liver
failure and visual impairment in Alpers-Huttenlocher syn-
drome due to autosomal recessive POLG mutations
(Naviaux and Nguyen 2004). Other defects of POLG are as-
sociatedwith valproate induced liver failure, further in support
that mtDNA replication is essential for optimal hepatocyte
function. Deoxyguanosine kinase (DGUOK) deficiency
causes mtDNA depletion with a predominant liver phenotype
though neurological features (nystagmus, muscular
hypotonia, psychomotor retardation) often accompany this
condition (Dimmock et al 2008). In patients carrying
MPV17 mutations hepatopathy is present with poor feeding,
hypoglycaemia, hypotonia and faltering growth and central
nervous system involvement usually appears later in the dis-
ease course (Uusimaa et al 2014). C10orf2 and SUCLG1 de-
ficiency may also result in an early-onset multisystem mito-
chondrial hepatoencephalomyopathy with hepatic mtDNA
depletion (Fellman and Kotarsky 2011; Van Hove et al
2010). Dysfunction of mitochondrial translation may also ac-
count for severe infantile liver failure (Kemp et al 2011)
caused by defects in mitochondrial translation elongation fac-
tors (GFM1, TSFM) (Balasubramaniam et al 2012; Vedrenne
et al 2012). A unique reversible infantile hepatopathy has been
shown in association with mutations in the mitochondrial
tRNA modifying factor TRMU (Zeharia et al 2009; Schara
et al 2011). In addition, liver dysfunction has been associated
with defects in mitochondrial proteins involved in single re-
spiratory chain complexes, such as SCO1 (complex IVassem-
bly factor) and BCS1L (complex III assembly factor) (Rahman
2013). The high number of mitochondrial disease genes af-
fecting the liver highlights the importance of mitochondria in
liver cell function.
Patients with mitochondrial liver diseases usually present
with defects of the respiratory chain enzymes in liver
tissue. However, the role of mitochondrial dysfunction in
the pathomechanism of severe liver disease of non-
mitochondrial or unknown origin leading to severe liver fail-
ure has not been investigated in detail before. This study in-
vestigates mitochondrial function in liver in a large cohort of
45 patients undergoing liver transplantation due to severe liver
disease of various aetiologies.
Materials and methods
Liver samples from 45 patients undergoing liver transplanta-
tion were investigated (Supplementary Table 1). The samples
were collected within 15 min after transplantation at the liver
Table 1 Summary of mitochondrial causes of liver failure with respiratory chain deficiency
Type of mitochondrial dysfunction Name Genes involved Respiratory chain defect
Disorders of mtDNA maintenance Hepatocerebral mitochondrial disease DGUOK, MPV17, POLG, SUCLG1, C10ORF2 Combined RC defect
Pearson syndrome Single mtDNA deletion Combined RC defect
Alpers-Huttenlocher syndrome POLG Combined RC defect
or normal
Disorders of mitochondrial
protein synthesis
Reversible infantile mitochondrial
hepatopathy
TRMU Combined RC defect
Mitochondrial tRNA synthetase defects EARS2, FARS2
Nuclear translation initiation-elongation
factors
GFM1, TSFM Combined RC defect
Defects of OXPHOS complex assembly Complex III assembly BCS1L Complex III
Complex IV assembly SCO1 Complex IV
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transplantation unit of the University of Essen after obtaining
patient consent, and were immediately frozen and were kept at
−80 °C until sample preparation. Liver samples were taken
from better preserved areas, without obvious tissue destruc-
tion and routine histological examination detected end stage
liver disease. Control liver samples were collected from do-
nated liver samples of healthy individuals (usually relatives of
patients). These samples were collected, stored and processed
by the samemethods as the patient samples. To avoid artefacts
due to inappropriate storage or sample handling, all analysed
samples were collected, kept frozen and analysed within a
period of 12months. The study has been approved by the local
research ethics committee. We did not apply special selection
criteria; we included patients undergoing liver transplantation
in our transplantation unit who agreed to study participation
and signed the informed consent form.
Analysis of mtDNA copy number
Measurement of mtDNA copy number was performed on
DNA extracted from liver as reported previously (Bulst et al
2009).We used 12 control liver DNA samples for determining
the control range.
Mitochondrial extraction from liver tissue and blue native
preparation
Unless specified all chemicals were purchased from Sigma
(Sigma Aldrich, UK). Liver tissue was weighed, thawed and
cut into small pieces using a scalpel and added to a glass
Elvehjem potter with ten volumes of Buffer A (0.32 M
Sucrose, 10 mM Tris–HCl and 1 mM EDTA) to the weight
of tissue according to the method of Fernandez-Vizarra with
small modifications (Fernández-Vizarra et al 2010).
Homogenisation was performed with 8 up and down strokes
at 600 rpm. The homogenate was then centrifuged at 1000 g
for 5 min. The supernatant was equally divided between tubes
for activity assay and BN PAGE. The remaining supernatant
for BN PAGE was centrifuged at 9000 g for 10 min and the
pellet resuspended in 100 uL buffer Awith digitonin (1 in 200
of weight of tissue). Each sample was incubated on ice for
10 min and then vortexed; 1 ml of a protease inhibitor tablet
(Roche, UK) in 10 ml PBS (PI/PBS) was added to dilute the
digitonin and the sample was centrifuged at 10,000 g for
10 min. The pellet was resuspended in 30–100 uL of MB2
buffer (0.5 ml 3× gel buffer (1.5 M aminocaproic acid, 150
mMBis-Tris, pH 7), 0.5 ml 2 M aminocaproic acid, 4 uL
500 mM EDTA) depending on its size. N-dodecyl B-D-
maltoside in PI/PBS was added to a final concentration of
1 %, vortexed, incubated on ice for 15 min and then centri-
fuged at 16,000 g for 30 min. The supernatant was removed
and saved (Leary and Sasarman 2009).
Biochemical activity assays
The measurement was performed as previously described
(Gómez-Durán et al 2011). Three cycles of freeze-thaw were
performed on each sample. Each assay was performed on a
Multiskan Ascent 96/384 Plate Reader (ThermoFisher
Scientific, UK). To establish a normal control range, we per-
formed the measurement on 12 control liver tissues. The ac-
tivities of citrate synthase (CS) and complex II were measured
by spectrophotometry as previously described (Gómez-Durán
et al 2011). Complex IVactivity was analysed as reduction of
cytochrome c at 550 nm as previously described (Gómez-
Durán et al 2011). All measured parameters were expressed
in specific activity per mg/protein in the sample. Total protein
was quantified by method of Bradford assay.
BN PAGE and immunoblotting
Electrophoresis of proteins was carried out in 3 to 15 % gra-
dient gels and 4 % stacking gel were prepared for BN PAGE
according to the protocol of Calvaruso et al (Calvaruso et al
2008). A GilsonMiniPuls 3 gradient gel mixer (Gilson, USA)
was used at a speed of 5.38 ml/min. SBG buffer (750 mmol/l
aminocaproic acid, 5 % Coomassie Brilliant Blue G250
Biorad, UK) was added to the samples and 2 ug of each sam-
ple used. The electrophoresis was run on a Consort EV202
power supply at 50 V for 20 min through the stacking gel, at
100 V until the blue dye front reached halfway down the gel
and at 150 V until all the blue dye had run out of the gel using
blue cathode buffer (400 ml cathode buffer (15 mmol/l Bis-
Tris, 50 mmol/l Tricine, pH 7), 0.08 g Coomassie Brilliant
Table 2 Number of patients with
deficiencies on BN PAGE,
respiratory chain enzyme
activities and mtDNA copy
numbers in the cohort of 45
patients
Diagnosis
(number of patients)
BN PAGE <50 % Complex II and IV <50 % mtDNA copy number <30 %
Acute liver failure (3) 3/3 (100 %) 3/3 (100 %) 3/3 (100 %)
Biliary atresia (9) 1/8 (13 %) 5/9 (56 %) 2/9 (22 %)
Cirrhosis (11) 3/10 (30 %) 6/11 (55 %) 2/11 (18 %)
Tumour (6) 3/5 (60 %) 2/6 (33 %) 2/6 (33 %)
Other (16) 0 4/16 (25 %) 1/16 (6 %)
Total 10/40 (25 %) 20/45 (44 %) 10/45 (22 %)
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Blue G250) in the upper reservoir and anode buffer (50 mmol/
l Bis-Tris, pH 7) in the lower reservoir. The gel was transferred
to a PVDF membrane, destained, blocked and incubated with
primary antibody to the respiratory chain complexes (complex
I subunit NDUFA9 – 2 ug/ml, complex II 70 kDa subunit –
0.2 ug/ml, complex III core 1 subunit – 1 ug/ml, complex IV
subunit 4–1 ug/ml, complex VATP synthase – 0.25 ug/ml (all
Abcam, UK)), a secondary rabbit anti-mouse antibody
(Dako, UK) (0.5 uL per ml) and then developed with
ThermoScientific Pierce ECL2 Western Blotting kit or
BioRad Clarity Western ECL solution. The signal was detect-
ed with the UVP BioSpectrum 500 Imaging System and the
intensity quantified using Image J software. Twelve control
liver samples were used as controls. Respiratory complexes
were normalised to porin and to complex II, which gave sim-
ilar results in 40 patients (Supplementary data 1). Because of
technically not acceptable results we had to exclude five pa-
tients from this analysis.
Statistical analysis
SigmaPlot version 11.0 (Systat Software, UK) was used for
statistical analysis. Comparisons of many groups were made
using a one way ANOVA. For non-normally distributed data,
a Kruskal-Wallis one way ANOVAwas automatically select-
ed. For comparisons between groups an unpaired t-test was
used. A value of p<0.05 was considered statistically signifi-
cant (*), p<0.01 very significant (**) and p<0.001 extremely
significant (***).
Results
Clinical presentation
The clinical presentations of the 45 patients, whose liver sam-
ples were analysed, are summarised in Table 2. The majority
of patients were children (≤16 years) with an early onset of
liver failure (30/45; 67 %). In children, biliary atresia was the
most frequent diagnosis (9/30), followed by progressive fa-
milial intrahepatic cholestasis (6/30), tumour (5/30) and
hyperoxaluria (4/30). The most frequent clinical presentation
in the 14 adults (>16 years) was cirrhosis due to alcoholic
liver disease (9/14). None of the patients showed clinical
signs of a potential mitochondrial disease, and they had no
increased lactate levels in serum. Patients in the acute liver
disease group had isolated liver presentation and no symp-
toms of other organs were noted to suspect mitochondrial
dysfunction. In patient 26 and 61 liver failure was triggered
by drug administration, in patient 53 the primary cause could
not have been identified.
MtDNA copy number
MtDNA copy number showed high variability— ten samples
had values ≤50 %, including all three patients with acute liver
failure. In four cases with cirrhosis (2), tumour (1) or other
conditions (1) we detected very high (>150 % of the control
mtDNA copy numbers) (Fig. 1a). We cannot exclude that
fibrosis has contributed to the low mtDNA copy numbers in
some of the samples.
Biochemical activity of respiratory chain enzymes
The activities of the respiratory chain enzymes complex II, IV
and citrate synthase were measured in this study. The majority
of patients studied in this cohort (40/45) had normal citrate
synthase activity, an indicator of the number of functional
mitochondria in the cell (Fig. 1). In contrast to citrate synthase,
we measured abnormally low (<50 %) activity of complex II
and/or complex IV in 20 patients (44 %), nine of them had
very low (<20 %) activities (Tables 1 and 2, Fig. 1b–d).
BN PAGE
In this cohort ten of 40 patients (25 %) showed mitochondrial
abnormalities on BN PAGE (Tables 1 and 2, Figs. 2 and 3). A
combined deficiency of many respiratory chain enzymes was
the most common type, however in a few cases the decreased
activity was only observed in a single enzyme affecting com-
plexes I-IV (Figs. 2 and 3). An isolated complex V defect was
not seen in any patient. Although abnormal respiratory com-
plexes were detected in some patients in each disease category
severe decreases of multiple enzymes were detected in all
three patients with acute liver failure.
Mitochondrial dysfunction in the different clinical groups
Acute liver failure
Two of three patients (patients 53 and 61) showed a severe
decrease and one (patient 26) a milder decrease in the levels of
all complexes of the respiratory chain on BN PAGE (Fig. 2a
and b). In support of these data we detected significantly re-
duced activities of complex II (p=0.008) and complex IV
(p=0.017) in all three patients and the activity of citrate syn-
thase and the mtDNA copy number were also lower than
controls indicating that a low number of mitochondria are
present in these patients (Fig. 2c–f). In fact, mtDNA copy
numbers were within the range suggestive of mtDNA deple-
tion. Sequencing of the DGUOK, POLG and MPV17 genes
did not reveal the causative mutation, however, it is possible
that the mtDNA depletion contributed to the liver failure in
these patients.
430 J Inherit Metab Dis (2016) 39:427–436
Biliary atresia
In biliary atresia one of eight patients (patient 44) had a clear
deficiency of complexes I and Von BN PAGE (Fig. 2g and h),
which was associated with unmeasurable activity of respira-
tory chain complex IV (Fig. 2j). On biochemical measurement
of enzyme activities two additional patients (patients 14 and
28) had a decreased complex IV activity (<50 % of control)
despite normal complex IV on BN PAGE in patient 14
(Fig. 2j). The mtDNA copy number was significantly in-
creased in patients 44 and 48, suggesting a compensatory
mitochondrial proliferation. Reduced mtDNA copy number
(<30 % of normal range) was found in two additional patients
in this group (patients 42 and 69).
Fig. 1 We show the distribution of mtDNA copy numbers and the
activities of respiratory chain complexes II, IV and citrate synthase in
45 patients with liver failure. One way ANOVA shows the effect of
liver failure on mtDNA copy number (a) and on the activities of
complex II (c), complex IV (d) and citrate synthase (b). Patients are
divided according to diagnosis and results are given as a percentage of
the control values
J Inherit Metab Dis (2016) 39:427–436 431
Cirrhosis
Three of ten patients (patients 45, 49 and 57) appeared to have
<50 % levels of oxidative phosphorylation complexes on BN
PAGE (Fig. 3a and b). Interestingly, the activity of complex II
was significantly decreased <50 % of normal (18–40 %) in six
patients with cirrhosis (Fig. 3c), while complex IVactivity also
indicated lower levels of activities in the same six patients
(Fig. 3d). Citrate synthase activity was within the normal range
in the majority of these patients, indicating that low complex II
and complex IV activity is not caused by a low number of
mitochondria. MtDNA copy number was also within the nor-
mal range, or even higher inmost patients with cirrhosis, except
for two patients, who had low mtDNA copy number in a path-
ological range (10–20 %) (Tables 1 and 2, Fig. 1a).
Tumours
In patients with tumours, results from BN PAGE were vari-
able, likely due to the heterogeneity of tumour types in this
cohort encompassing hepatocellular carcinoma (n = 1),
hepatoblastoma (n=3) and two not well characterised tu-
mours (n=2) (Fig. 3e and f). Three out of five patients had
deficiencies of multiple respiratory chain enzymes on BN
PAGE, and one (patient 36) had increased levels of the respi-
ratory chain complexes I, III, IV and V.
In three of these cases (patients 36, 41 and 52) tumour
tissue and non-affected healthy or cirrhotic tissue were
taken from the same patient at the time of transplanta-
tion. In one of these patients (patient 52) tumour tissue
showed lower expression of respiratory chain complexes
Acute liver failure Biliary atresia
a b g
c d
h
e f i j
Fig. 2 BNPAGE analysis andmeasurement of enzyme activities in acute
liver failure in acute liver failure and biliary atresia.Acute liver failure. a
Respiratory complexes isolated from control and patients with acute liver
failure were separated using blue native gel electrophoresis on gradient
Bis-Tris acrylamide gels. b Quantification of respiratory complexes was
carried out with band densitometry. Graphs show the level of complexes
relative to the control samples. Porin was used as a loading control. Red
dotted line indicates 50% of the control samples. Complex activities were
measured spectrophotometrically as described in Methods. Data
presented in percent changes relative to the control samples. c Citrate
synthase activity. Combined data from all three patients shows a
significant decrease (p = 0.045) in activity when compared to the
control group. d Complex II activity. Combined data from all three
patients shows a significant decrease (p = 0.008) in activity when
compared to the control group. e Complex IV activity. Combined data
from all three patients shows a significant decrease (p< 0.017) in activity
when compared to the control group. fmt-DNA copy number. Error bars
represent standard deviation. Biliary atresia. gMitochondrial complexes
isolated from control and liver failure patients’ liver were separated using
blue native gel electrophoresis on gradient Bis-Tris acrylamide gels. h
Quantification of respiratory complexes was carried out with band
densitometry. Graphs represent the level of complexes relative to the
control samples. Band intensities were normalised to complex II. Red
dotted line indicates 50 % of the control samples. i Complex II activity.
j Complex IV activity. Error bars represent standard deviation
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on BN PAGE both compared to healthy tissue from the
same liver and to controls, and in patient 36 expression
of complexes I and IV was increased in tumour tissue
compared to healthy tissue as well as controls confirming
that the respiratory chain alterations are characteristic for
the tumour cells.
Biochemical measurement of enzyme activities de-
tected lower complexes II and/or IV activities in two
out of six patients (patients 2 and 41, 33 %) with tu-
mours, which was significant for the complex II de-
crease (Fig. 3g). In two patients the mtDNA copy num-
ber was decreased ≤30 %. On the contrary, patient 41
had a substantially elevated mtDNA copy number, while
in the same patient biochemical measurement of com-
plex II was significantly reduced (Fig. 3h, Tables 1 and
2, Fig. 1). This may be specific for the tumour cells in
this patient.
Other conditions
We studied six patients with progressive familial intrahepatic
cholestasis, four patients with hyperoxaluria, three patients
with cystic liver and single cases with Budd Chiari syndrome,
Alagille syndrome and congenital liver fibrosis. BN PAGE did
not reveal significant defects in any of these patients, however
we detected some decrease in complex II and/or IV activities
in four patients from various diseases within the Bother^
group. Low mtDNA copy number (<30 %) was detected in
only one patient from this group (Tables 1 and 2).
Liver tumoursLiver cirrhosis
a e
f
g h
b
c d
Fig. 3 BN PAGE and measurement of enzyme activities in cirrhosis and
liver tumours. Liver cirrhosis. aMitochondrial complexes isolated from
control and cirrhosis patients’ liver were separated using blue native gel
electrophoresis on gradient Bis-Tris acrylamide gels. b Quantification of
respiratory complexes was carried out with band densitometry. Graphs
represent the level of complexes relative to the control samples. Band
intensities were normalised to complex II. Red dotted line indicates
50 % of the control samples. c Complex II activity. d Complex IV
activity. Error bars represent standard deviation. Liver tumours. e
Mitochondrial complexes isolated from control and tumour patients’
liver were separated using blue native gel electrophoresis on gradient
Bis-Tris acrylamide gels. f Quantification of respiratory complexes was
carried out with band densitometry. Graphs represent the level of
complexes relative to the control samples (100 %). Band intensities
were normalised to complex II. Red dotted line indicates 50 % of the
control samples. g Complex II activity. h Complex IV activity. Error
bars represent standard deviation
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Discussion
End stage liver disease can be caused by a variety of conditions
including viral infections, inherited metabolic diseases, drug
toxicity, defects of biliary ducts, cholestasis or tumours, and
in many cases the aetiology remains unclear. Even in condi-
tions with known causes such as tumours and progressive fa-
milial intrahepatic cholestasis the reasons for progression to
end stage liver disease involve various pathomechanisms. We
studied liver tissue samples in a large, representative cohort of
45 patients undergoing liver transplantation for various forms
of liver disease and detected mitochondrial abnormalities (mi-
tochondrial respiratory chain deficiency and/or abnormal
mtDNA copy number) in several cases. This cohort is repre-
sentative of a wide range of severe liver conditions and is the
first to systematically investigate mitochondrial function in se-
verely affected liver at the time of transplantation. All patients
had a severe, isolated liver manifestation and no involvements
of other organs supporting mitochondrial disease such as brain
and skeletal muscle were noted at the time of transplantation.
In acute liver failure all three patients had abnormal mito-
chondrial function supported by reduced complexes on BN
PAGE, decreased activities of complexes II and IV and low
mtDNA copy numbers. These results indicate that mtDNA
depletion may lead to mitochondrial dysfunction and acute
liver cell death in these patients. Although screening for
known genetic causes of hepatic mtDNA depletion did not
reveal the primary molecular defect in our patients, it is still
possible that mutations in novel genes or in known genes
where a different clinical presentation is expected are under-
lying mtDNA depletion in these cases. However we cannot
exclude that the detected mitochondrial abnormalities in these
patients are due to a low number of mitochondria in the dis-
eased liver cells as a result of a sudden unknown disease
mechanism.
Helbling et al 2013 studied mtDNA copy numbers in 244
patients with various forms of liver disease leading to hepatic
failure requiring liver transplantation. They detected low
mtDNA copy numbers in 66 % of the cases and in half of
these patients the mtDNA copy number was in the range of
definite mtDNA depletion (Helbling et al 2013). Screening for
mutations in known genes associated with mtDNA depletion
revealed heterozygous variants in POLG and DGUOK, how-
ever, a causative effect of these variants to cause mtDNA
depletion and liver failure has not been shown, and no other
mitochondrial studies were performed in support of a mito-
chondrial aetiology of liver dysfunction. The authors suggest
that patients with acute liver failure in association with
mtDNA depletion may have an underlying genetic predispo-
sition or a mitochondrial disease, however, no experimental
evidence has been shown in support of this hypothesis.
MtDNA depletion has been detected in 50 % (50/100) of
children with multiple respiratory chain enzyme deficiency
and most of these patients (32/50; 64%) presented with severe
neonatal onset liver involvement (Sarzi et al 2007). However,
the causative mutations could not be identified in half of these
cases, illustrating further genetic heterogeneity (Sarzi et al
2007). Another study performed whole exome sequencing in
three children with acute liver failure and identified pathogen-
ic mutations in MPV17, SERAC1 and NOTCH2, despite the
lack of characteristic clinical phenotypes for these genes
(Vilarinho et al 2014). Based on our data and previous reports
rare genetic causesmay be responsible for acute liver failure in
a number of patients and next generation sequencing studies
may define further novel mitochondrial phenotypes.
The detection of mitochondrial abnormalities in a relatively
large number of patients with a wide range of diagnoses raises
the possibility that oxidative phosphorylation may be a sec-
ondary result of a more complex cellular phenotype and can
contribute to the hepatocellular dysfunction in various condi-
tions. In biliary atresia we detected variable mitochondrial
alterations (low complex IV activity, decreased complex I
and Von BN PAGE, low mtDNA copy number) in 20–50 %
of patients. However the lack of consequent findings in this
disease group did not allow a better understanding of their role
in the pathomechanism of the disease. It is possible that they
are linked with certain stages of hepatocellular dysfunction, as
supported by the detection of low mtDNA copy numbers in
leukocytes of patients with early stage biliary atresia, suggest-
ing a role of inflammatory reaction and secondary mitochon-
drial DNA damage in this condition (Tiao et al 2007).
Variable findings were detected in our study in patients
with cirrhosis. About half of cirrhosis patients did not show
any abnormalities, however, others had defects in one or more
complexes or showed copy number abnormalities. The de-
creased activity of complex II was quite common in cirrhosis
(55 %). It may be related to the disease progression, however,
currently we have no explanation why complex II is most
affected in this disease group. Chronic ethanol consumption
has been shown to affect mitochondrial function by altering
the mitochondrial permeability transition pore in the liver,
suggesting a potential mechanism (King et al 2014).
In support of the secondary aetiology of mitochondrial al-
terations in cirrhosis, mitochondrial DNA re-arrangements
and low copy numbers have been previously detected in pa-
tients with alcohol-induced end stage liver disease and their
role has been suggested in the pathophysiology of the disease
(Tang et al 2012).
We detected very diverse findings in liver tumours.
While five out of six patients with tumours had deficient
respiratory chain enzymes, one patient showed increased
complexes on BN PAGE. Contrasting results were de-
tected in the different tumours in the activity assays
and two patients had lower and one patient very high
mtDNA copy numbers on quantitative PCR analysis
compared to the healthy tissue from the same liver,
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suggesting that cancer cells have altered mitochondrial
metabolism. The role of mitochondria has been inten-
sively studied in cancer and the pharmacological inhibi-
tion of mitochondrial metabolism is emerging as a po-
tential therapeutic strategy in some cancers (Ahn and
Metallo 2015). In support of our findings, somatic
mtDNA mutations and decreased mtDNA copy number
have been detected in hepatocellular carcinoma, suggest-
ing that a mitochondrial dysfunction-activated signalling
cascade may play an important role in the disease pro-
gression (Hsu et al 2013). A possible link between
mtDNA depletion and tumorigenesis has been suggested
by the detection of hepatocellular carcinoma in a patient
with DGUOK deficiency (Freisinger et al 2006).
Our data highlight that mitochondrial dysfunction may
be secondary in a wide range of liver diseases of non-
mitochondrial aetiology, although exclusion of primary mi-
tochondrial causes has only been performed in a few se-
lected cases. Detection of respiratory chain dysfunction in
liver disease requiring transplantation is not sufficient to
make the diagnosis of a mitochondrial disease, and should
not restrict the inclusion of patients for liver transplanta-
tion. Furthermore, recent data suggest that liver transplan-
tation may provide clinical benefit for patients with prima-
ry mitochondrial disease, especially when the clinical pre-
sentation is likely to be restricted to liver (Dimmock et al
2008; Hynynen et al 2014).
In conclusion, this study provides good evidence that
mitochondrial dysfunction is present in patients undergo-
ing transplantation due to various types of primary liver
disease. We suggest that mitochondrial disease should be
investigated in patients with acute liver failure of un-
known cause, although finding the molecular cause can
be difficult due to genetic heterogeneity. Although mito-
chondrial respiratory chain deficiencies and mtDNA copy
number abnormalities are helpful to identify patients with
a potentially primary mitochondrial liver disease, a criti-
cal interpretation of these data is needed. Further inves-
tigation of the role of mitochondrial dysfunction in end
stage liver disease in other, non-mitochondrial hepatic
disorders may reveal novel pathways, which may be
targeted to improve mitochondrial function and to pre-
vent or ameliorate disease progression.
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